Is acute myeloid leukemia treatment possible without transplant?

Yes, for favorable-risk AML or elderly patients unfit for transplant, chemotherapy with or without targeted therapy can achieve remission.

What is the AML transplant success rate?

With matched donors and early transplant during first remission, success rates range between 50%–70% depending on age, risk factors, and MRD status.

How long does acute myeloid leukemia (AML) treatment take?

Induction chemotherapy usually takes 4–6 weeks. Consolidation or transplant requires another 4–8 weeks. Post-transplant recovery may last several months.

How is acute myeloid leukemia (AML) different from chronic myeloid leukemia (CML)?

AML is acute and aggressive, requiring immediate intensive therapy. CML is a chronic disease often managed long-term with oral targeted drugs like imatinib

What is acute myeloid leukemia (AML) remission treatment?

It includes post-chemotherapy or post-transplant follow-up, MRD monitoring, immunosuppression tapering, and infection prevention to avoid relapse.

Is acute myeloid leukemia (AML) common in India?

Yes, AML is one of the most common acute leukemias in adults, and its incidence is rising in urban populations.

Can children get AML?

Yes. AML in children and adolescents requires pediatric-specific treatment protocols and is managed by our expert pediatric oncology team.

What is multiple myeloma and how is it different from other blood cancers?

Multiple myeloma is considered a cancer of plasma cells, a type of white blood cell that helps fight infection. Unlike leukemia or lymphoma, it majorly affects the bone marrow and skeletal system.

What are the early signs of multiple myeloma?

Early signs include persistent bone pain, frequent infections, unexplained fatigue, anemia, kidney dysfunction, and high calcium levels.

How is multiple myeloma diagnosed at BMT Next?

We use a combination of blood tests (SPEP, IFE, FLC), bone marrow biopsy, PET-CT or MRI, and FISH cytogenetic studies to confirm diagnosis and risk stratify the disease.

What is the role of FISH cytogenetics in myeloma diagnosis?

FISH identifies genetic abnormalities like del(17p), t(4;14), or 1q gain, which help us predict prognosis and customize treatment.

Is bone marrow transplant mandatory for all myeloma patients?

No. Autologous stem cell transplant (ASCT) is recommended for eligible patients to prolong remission, but alternatives exist for transplant-ineligible individuals.

What is CAR-T therapy and is it available at BMT Next?

CAR-T therapy involves genetically modifying a patient’s own T-cells to fight myeloma. It is available through clinical access programs at BMT Next.

. What are the treatment options for relapsed or refractory myeloma?

Options include immunomodulators like Pomalidomide, monoclonal antibodies like Daratumumab, BiTE therapies, and CAR-T cells.

How does BMT Next monitor treatment response?

We use MRD (minimal residual disease) testing via flow cytometry or NGS to monitor the depth of remission after treatment.

Are there different types of multiple myeloma?

Yes, including smoldering myeloma (asymptomatic), active myeloma (requiring treatment), and relapsed/refractory myeloma.

What support services are offered at BMT Next for myeloma patients?

Patients receive nutritional counseling, pain management, physiotherapy, renal care, and emotional wellness support throughout treatment.

What makes BMT Next the best center for multiple myeloma treatment in India?

BMT Next offers the best multiple myeloma treatment in India through its expert-led centers in Gurgaon, Hisar, Faridabad, and Mauritius. Our strength lies in bone marrow transplant excellence, MRD-based treatment, next-level FISH cytogenetics, and access to CAR-T and BiTE therapy. Patients across North India and internationally choose BMT Next for high-quality, affordable, and personalized plasma cell cancer treatment.

How can patients from Mauritius access myeloma care at BMT Next?

Our international patient desk helps with appointment scheduling, visa support, travel coordination, and follow-up teleconsultation.

How often should follow-up occur after myeloma treatment?

Follow-up is typically every 3–6 months with blood tests, MRD monitoring, and imaging when needed.

What is lenalidomide maintenance and why is it important?

Lenalidomide is used after transplant or initial therapy to maintain remission and delay progression. It is a cornerstone of long-term management.

Are affordable treatment packages available for myeloma at BMT Next?

Yes. We offer cost-effective care across Hisar, Faridabad, and Gurgaon with insurance, CGHS, and EMI support.

What is the success rate of bone marrow transplant in India?

At leading centers like BMT Next, the success rate for bone marrow transplant ranges between 70% to 90%, depending on the disease type, patient condition, and transplant match. Conditions like thalassemia, aplastic anemia, and acute leukemia show high cure rates when treated early.

How much does a bone marrow transplant cost in India?

The cost varies between ₹8 to ₹25 lakhs, based on the type of transplant. Autologous BMTs are usually less expensive than allogeneic or haploidentical transplants. BMT Next offers transparent packages in Gurgaon, Faridabad, Hisar, and Mauritius with financial counseling support.

How long does a bone marrow transplant take?

The full procedure—including pre-evaluation, transplant, and initial recovery—typically takes 4 to 6 weeks. Post-discharge monitoring continues for 6 to 12 months depending on the patient’s immune recovery.

Who can be a donor for bone marrow transplant?

Donors may be siblings, matched unrelated individuals, or half-matched (haploidentical) family members. At BMT Next, we conduct HLA typing and also work with global donor registries if a family match isn’t available

Is bone marrow transplant painful?

The transplant itself is not painful. It’s a stem cell infusion given through a vein, very similar to a blood transfusion. Pre-transplant chemotherapy may cause side effects, which are managed by our transplant care team.

Which diseases are treated with bone marrow transplant?

We treat leukemia, lymphoma, multiple myeloma, aplastic anemia, thalassemia, sickle cell anemia, MDS, and rare immunodeficiency syndromes. BMT Next specializes in both adult and pediatric BMTs across all these conditions.

Can international patients get bone marrow transplant in India?

Yes. Through our Mauritius center, international patients from Africa, the Middle East, and Indian Ocean islands can access India’s best BMT care with visa assistance, translator support, and telemedicine follow-up.

What are the risks of bone marrow transplant?

Like any major medical procedure, BMT carries risks such as infection, graft-versus-host disease (GVHD), and delayed engraftment. However, at BMT Next, we use strict infection control, ICU monitoring, and early GVHD management to minimize complications.

Why is BMT Next considered among the best bone marrow transplant centers in India?

With over 3,000+ transplants performed, MRD-guided therapy, internationally trained specialists, and a strong presence in Gurgaon, Faridabad, Hisar, and Mauritius, BMT Next combines experience with accessibility and affordability.

How soon should I consult for a bone marrow transplant?

Early consultation is critical—especially for high-risk leukemia, aplastic anemia, or relapsed cancers. Delays can affect survival. Contact BMT Next today to schedule a transplant evaluation at your nearest center.

best acute lymphocytic leukemia treatment in india

Services

let us helping you by make an appointment

Lorem ipsum dolor sit amet consectetur.

At BMT Next, we provide comprehensive, evidence-based treatment for acute lymphocytic leukemia (ALL) in India, with specialized services in Hisar, Faridabad, Gurgaon, and Mauritius. Acute Lymphocytic Leukemia (ALL) is a rapidly progressing cancer of the white blood cells that requires expert-led, protocol-driven care. Our center is known for delivering personalized chemotherapy, precision diagnostics, bone marrow transplant (BMT), and cutting-edge immunotherapies to patients across age groups and disease stages.

We focus on delivering high remission and survival rates for children and adults diagnosed with ALL, including difficult-to-treat subtypes such as Philadelphia chromosome-positive ALL (Ph+ ALL), T-cell ALL, and relapsed or refractory disease. We proudly serve patients across India, Africa, and the Indian Ocean region, combining clinical excellence with compassionate care.

Why Choose BMT Next for Acute Lymphocytic Leukemia (ALL) Treatment?

BMT Next stands out for its track record of over 5000+ bone marrow transplants, 20+ years of experience in leukemia management, and a multidisciplinary team approach. Our clinical protocols are tailored using insights from molecular diagnostics and MRD (Minimal Residual Disease) tracking, offering a competitive edge over generalized leukemia treatment programs.

We are equipped to treat:

Pediatric and adult B-cell and T-cell acute lymphoblastic leukemia
High-risk and relapsed ALL cases using advanced BMT
Ph+ ALL with targeted therapies and transplant integration
Refractory ALL with access to CAR-T therapy and BiTE immunotherapy

Accurate Diagnosis and Risk Stratification

The foundation of successful ALL treatment lies in accurate diagnosis and molecular risk classification. We utilize:

Complete blood counts with differential
Bone marrow aspiration and biopsy
Flow cytometry for lineage classification
Cytogenetics and FISH (e.g., BCR-ABL1, TCF3-PBX1, MLL rearrangements)
NGS (Next Generation Sequencing) for identifying rare mutations
MRD testing post-induction and consolidation to guide therapy intensification

Chemotherapy Protocols Tailored to Acute Lymphocytic Leukemia (ALL) Subtypes

We follow globally accepted regimens such as BFM (Berlin-Frankfurt-Munich) and COG (Children’s Oncology Group), adapted to the Indian population.

Treatment Phases Include:

Induction Chemotherapy to achieve remission (Vincristine, PEG-Asparaginase, Dexamethasone)
Consolidation and Intensification with Methotrexate, Cytarabine, and 6-MP
CNS Prophylaxis through intrathecal chemotherapy
Maintenance Phase lasting 2–3 years for pediatric patients

Bone Marrow Transplant (BMT) for High-Risk and Relapsed ALL

Our centers in Gurugram, Hisar and Faridabad have advanced Bone Marrow Translant units with class 1000 HEPA filtration, positive pressure rooms, and continuous monitoring of immunosuppression and engraftment.

Immunotherapy and Advanced Options for Refractory ALL

Blinatumomab (BiTE): Bispecific antibody for CD19+ B-cell ALL
Inotuzumab ozogamicin: ADC targeting CD22 in relapsed B-ALL
Tyrosine kinase inhibitors (Imatinib, Dasatinib, Ponatinib) for Ph+ ALL
CAR-T cell therapy via partnerships with CAR-T centers in India

These options have shown remission rates of over 70% in otherwise incurable patients and are an integral part of our salvage therapy strategy.

Pediatric Acute Lymphocytic Leukemia (ALL) Excellence at BMT Next

We are India’s leading pediatric leukemia center. Our pediatric-specific services include:

Custom pediatric chemotherapy protocols with 90%+ survival in standard-risk B-ALL
Support for children with Down syndrome or other high-risk features
Integrated pediatric endocrinology and neurology teams for post-treatment care
Schooling continuation, play therapy, and psychosocial support
Sedation-free bone marrow procedures and pediatric-friendly environments

Geographic Reach – Centers of Excellence

Hisar: High-volume transplant center with advanced labs and round-the-clock leukemia care
Faridabad: Pediatric-focused hematology unit with ICU and transplant facilities
Gurgaon: Our flagship center for high-risk leukemia cases, genomic testing, and trial enrollment
Mauritius: International coordination unit providing continuity for African and island-based patients

Need Help?

FAQs

What is acute lymphocytic leukemia (ALL)?

ALL is a fast-growing cancer of the bone marrow and blood that affects lymphoid precursor cells. It occurs in both children and adults and requires immediate, specialized treatment.

What are the early symptoms of Acute Lymphocytic Leukemia (ALL)

Common symptoms include fatigue, infections, bruising or bleeding, bone pain, and swollen lymph nodes. Prompt diagnosis is essential.

How is ALL diagnosed at BMT Next?

We use CBC, bone marrow biopsy, flow cytometry, cytogenetics (e.g., BCR-ABL1), MRD testing, and next-generation sequencing to confirm the diagnosis and subtype.

What is the success rate for pediatric Acute Lymphocytic Leukemia (ALL) at BMT Next?

In standard-risk pediatric ALL, our survival rates exceed 94%, aligning with top international benchmarks.

What is the role of bone marrow transplant in ALL?

BMT is offered to patients with high-risk features, poor response to induction therapy, relapsed disease, or specific cytogenetic abnormalities like Ph+ ALL.

Can adults with ALL also be treated at BMT Next?

Yes. We treat adult ALL using age-adapted protocols and offer reduced-intensity transplant regimens when needed.

What targeted therapies do you offer for relapsed or refractory Acute Lymphocytic Leukemia (ALL)?

We provide access to Blinatumomab (BiTE), Inotuzumab ozogamicin, and TKIs for Ph+ ALL. CAR-T therapy is coordinated with leading centers in India.

How does BMT Next support international patients from Mauritius or Africa?

We offer virtual consultations, visa and travel assistance, multilingual care coordination, and continuity of treatment between India and Mauritius.

Is CAR-T cell therapy available for Acute Lymphocytic Leukemia (ALL)at BMT Next?

Yes. We collaborate with accredited CAR-T therapy partners to treat CD19+ relapsed/refractory ALL cases.

How is MRD testing used to guide treatment?

MRD (Minimal Residual Disease) testing after induction and consolidation phases helps assess treatment effectiveness and guides the need for BMT.

Accordion Title

Accordion Content

What are the side effects of chemotherapy for Acute Lymphocytic Leukemia (ALL)?

Side effects include neutropenia, infections, nausea, hair loss, and fatigue. We manage toxicity through supportive care and growth factor use.

Do you provide fertility preservation for young ALL patients?

Yes. We offer fertility counseling and options like sperm banking and ovarian tissue preservation before intensive chemotherapy or transplant.

How long is treatment for acute lymphocytic leukemia?

Pediatric ALL treatment typically lasts 2–3 years. Adult protocols are shorter but may include transplant or advanced therapies.

What makes BMT Next different from other leukemia centers?

We provide MRD-guided treatment, access to immunotherapy and transplant, global referrals, and unmatched survival outcomes in India.

How can I book a second opinion at BMT Next?

You can request a virtual or in-person second opinion by sharing your reports through our patient portal or contacting our coordination team directly.

Why is BMT Next considered the best center for acute lymphocytic leukemia (ALL) treatment in Gurgaon (Gurugram)?

BMT Next in Gurgaon is equipped with advanced genomic testing, CAR-T therapy access, expert-led transplant services, and participation in international clinical trials. It offers personalized care for both pediatric and adult ALL patients, combining technology, experience, and outcomes that meet global standards.